GOECP/SEOR radiotherapy guidelines for small-cell lung cancer

Table 1 Chronological changes in the combined treatment of small cell lung cancer

Chronological changes in SCLC treatment
Ref.	Stage (LS or ES)	Phase	Treatment	Median survival	5-yr survival	P value	Level of evidence
Miller et al[4] 1969	LS	III	RT	28.5 wk; 43 wk	1%; 5%	0.04	A I
Bergsagel et al[8] 1972	LS	III	RT; RT + Ch	21 wk; 42 wk	NR	< 0.05	A I
Einhorn et al[13] 1976	LS	II	RT + PCT	12 mo	10%		C III
Bunn et al[18] 1987	LS	III	PCT; PCT + RT	12 mo; 15 mo	10%; 15%	< 0.05	A I
Turrisi et al[27] 1988	LS	II	Early AHF-RT + CE	23 mo	30% at 3 yr		C III
Murray et al[26] 1993	LS	III	Early RT + CE; late RT + CE	21 mo; 19 mo	20%; 13%	< 0.05	A I
Pignon et al[21] 1992	LS	Meta-analysis	PCT (no CE); PCT (no CE) + TRT	< 14% mortality	> 5% at 3 yr	0.001	A I
Jeremic et al[29] 1997	LS	III	Early AHF-RT + CE; late AHF-RT + CE	36 mo; 34 mo	30%; 15%	0.0027	A I
Turrisi et al[31] 1999	LS	III	Early AHF-RT + CE; early NFRT + CE	23 mo; 19 mo	26%; 16%	0.04	A I
Jeremic et al[41] 1999	ES	III	PCT + RT + PCI; PCT + PCI	17 mo; 11 mo	9.1%; 3.7%	0.0041	A I
Aupérin et al[33] 1999	LS	Meta-analysis	PCI; no PCI	> 6% at 3 yr			A I
Takada et al[30] 2002	LS	III	Early AHF-RT + CE; late AHF-RT + CE	31.3 mo; 20.8 mo	24%; 18%	< 0.05	A I
Slotman et al[38] 2007	ES	III	CE + PCI; CE		27% at 1 yr; 13% at 1 yr	< 0.001	A I
Slotman et al[42] 2015	ES	III	CE + PCI; CE + TRT + PCI		3% at 3 yr; 13% at 3 yr	< 0.03	A I
Faivre-Finn et al[43] 2017	LS	III	CE + AHF-RT 45 Gy; CE + NFRT 66 Gy	29 mo; 19 mo	34%; 31%	NS	A I

LS: Limited-stage; ES: Extensive-stage; TRT: Thoracic radiotherapy; AHF-RT: Accelerated hyperfractionated radiotherapy; NFRT: Normofractionated radiotherapy; Ch: Chemotherapy; PCT: Polychemotherapy; PCI: Prophylactic cranial irradiation; CE: Cisplatin + etoposide; NS: Not significant.